Stem cells help to control
progression of early Parkinson's disease
The results of stem cell therapy
with multipotent mesenchymal stromal cells (MMSCs) both on animal models and in
clinical trials confirm that such approaches may slow the progression of
Parkinson’s disease and reduce symptoms, as well as lower adverse effects of
existing medications.
Studies of efficacy and the safety
of autologous or donor MMSCs when implanted into the specific regions of the
brain have been conducted since 2009. About half of the patients showed a
positive response within the observation period
• Reduced rigidity.
• Improved speech.
• Minimal tremors.
• Ability to do routine activities without much difficulty.
• Ability to walk for longer distances.
• Improved swallowing.
• Reduced involuntary movements.
• Increased independence during daily activities.
• Overall improvement assessed by the unified Parkinson’s disease rating scale
• Improved speech.
• Minimal tremors.
• Ability to do routine activities without much difficulty.
• Ability to walk for longer distances.
• Improved swallowing.
• Reduced involuntary movements.
• Increased independence during daily activities.
• Overall improvement assessed by the unified Parkinson’s disease rating scale
It was also noted that patients at
an early stage of Parkinson’s disease treated with stem cells often did not
experience disease progression and had more pronounced clinical improvement
when compared to patients treated at the later stages of the disease
Reference: Swiss Medica
No comments:
Post a Comment